Eiger BioPharmaceuticals, Inc. Announces 1-For-30 Reverse Stock Split
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will